Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Izzy who wrote (5589)	10/27/1998 3:02:00 AM
From: John Romeo	Read Replies (1) of 6136

My understanding is per company press releases this will be a 2nd generation protease inhibitor your dates are right. I'm sure when the time comes they will mix and match this with many other drugs including viracept.We'll just have to wait. Last summer at the Geneva conference i believe,this was the one where Sustiva killed the P.I. company's, agph came out with a number of new co-partnered new drug candidates.Development in this order,Remune,NNRTI,2nd generation P.I. japan. The company made it clear after the conference they will not rest with just viracept, their intent is to build an HIV franchise.Somewhat like Glaxo is doing Now. I agree with you this product numbering, naming is confusing I'll email or call and ask to update the site if more people do it, it can be done, we need more than 2 emails or phone calls, so everyone rise to the occasion. regards John L. R.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next